<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom" xmlns:content="http://purl.org/rss/1.0/modules/content/" xmlns:dc="http://purl.org/dc/elements/1.1/">
<channel>
<title>心血管高分期刊</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/rss-feed/?feed_id=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;utm_source=Chrome&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240508000928&amp;v=2.18.0.post9+e462414&amp;utm_campaign=pubmed-2&amp;utm_medium=rss
    <description>心血管高分期刊: Latest results from PubMed</description>
<atom:link href="https://pubmed.ncbi.nlm.nih.gov/rss-feed/?feed_id=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;utm_source=Chrome&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240508000928&amp;v=2.18.0.post9+e462414&amp;utm_campaign=pubmed-2&amp;utm_medium=rss" rel="self"></atom:link>
<docs>http://www.rssboard.org/rss-specification</docs>
<generator>PubMed RSS feeds (2.18.0.post9+e462414)</generator>
<language>en</language>
<lastbuilddate>Wed, 08 May 2024 04:09:29 +0000</lastbuilddate>
<pubDate>Tue, 07 May 2024 06:00:00 -0400</pubDate>
<ttl>120</ttl>
<item>
<title>Non-traditional risk factors: built environment assessed by Google Street View, syphilis, and rheumatoid arthritis</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38713840/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240508000928&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2024 May 7;45(17):1489-1493. doi: 10.1093/eurheartj/ehae261.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38713840/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240508000928&v=2.18.0.post9+e462414">38713840</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae261>10.1093/eurheartj/ehae261</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38713840</guid>
<pubDate>Tue, 07 May 2024 06:00:00 -0400</pubDate>
<dc:creator>Filippo Crea</dc:creator>
<dc:date>2024-05-07</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Non-traditional risk factors: built environment assessed by Google Street View, syphilis, and rheumatoid arthritis</dc:title>
<dc:identifier>pmid:38713840</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae261</dc:identifier>
</item>
<item>
<title>Rheumatoid arthritis and peripartum cardiovascular complications: focusing on non-traditional cardiovascular risk factors to improve maternal outcomes</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38713839/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240508000928&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2024 May 7;45(17):1537-1539. doi: 10.1093/eurheartj/ehae164.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38713839/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240508000928&v=2.18.0.post9+e462414">38713839</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae164>10.1093/eurheartj/ehae164</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38713839</guid>
<pubDate>Tue, 07 May 2024 06:00:00 -0400</pubDate>
<dc:creator>Sarah Goldstein</dc:creator>
<dc:creator>Kathryn Lindley</dc:creator>
<dc:date>2024-05-07</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Rheumatoid arthritis and peripartum cardiovascular complications: focusing on non-traditional cardiovascular risk factors to improve maternal outcomes</dc:title>
<dc:identifier>pmid:38713839</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae164</dc:identifier>
</item>
<item>
<title>Ultrasound Neuromodulation of an Anti-Inflammatory Pathway at the Spleen Improves Experimental Pulmonary Hypertension</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38712557/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240508000928&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS: sFUS causes dose-dependent, sustained improvement of hemodynamic, autonomic, laboratory, and pathological manifestations in 2 models of experimental pulmonary hypertension. Mechanistically, sFUS normalizes immune cell populations in the spleen and downregulates inflammatory genes and pathways in the lung, many of which are relevant in human disease.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Circ Res. 2024 May 7. doi: 10.1161/CIRCRESAHA.123.323679. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: Inflammation is pathogenically implicated in pulmonary arterial hypertension; however, it has not been adequately targeted therapeutically. We investigated whether neuromodulation of an anti-inflammatory neuroimmune pathway involving the splenic nerve using noninvasive, focused ultrasound stimulation of the spleen (sFUS) can improve experimental pulmonary hypertension.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: Pulmonary hypertension was induced in rats either by Sugen 5416 (20 mg/kg SQ) injection, followed by 21 (or 35) days of hypoxia (sugen/hypoxia model), or by monocrotaline (60 mg/kg IP) injection (monocrotaline model). Animals were randomized to receive either 12-minute-long sessions of sFUS daily or sham stimulation for 14 days. Catheterizations, echocardiography, indices of autonomic function, lung and heart histology and immunohistochemistry, spleen flow cytometry, and lung single-cell RNA sequencing were performed after treatment to assess the effects of sFUS.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: Splenic denervation right before induction of pulmonary hypertension results in a more severe disease phenotype. In both sugen/hypoxia and monocrotaline models, sFUS treatment reduces right ventricular systolic pressure by 25% to 30% compared with sham treatment, without affecting systemic pressure, and improves right ventricular function and autonomic indices. sFUS reduces wall thickness, apoptosis, and proliferation in small pulmonary arterioles, suppresses CD3<sup>+</sup> and CD68<sup>+</sup> cell infiltration in lungs and right ventricular fibrosis and hypertrophy and lowers BNP (brain natriuretic peptide). Beneficial effects persist for weeks after sFUS discontinuation and are more robust with early and longer treatment. Splenic denervation abolishes sFUS therapeutic benefits. sFUS partially normalizes CD68<sup>+</sup> and CD8<sup>+</sup> T-cell counts in the spleen and downregulates several inflammatory genes and pathways in nonclassical and classical monocytes and macrophages in the lung. Differentially expressed genes in those cell types are significantly enriched for human pulmonary arterial hypertension-associated genes.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: sFUS causes dose-dependent, sustained improvement of hemodynamic, autonomic, laboratory, and pathological manifestations in 2 models of experimental pulmonary hypertension. Mechanistically, sFUS normalizes immune cell populations in the spleen and downregulates inflammatory genes and pathways in the lung, many of which are relevant in human disease.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38712557/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240508000928&v=2.18.0.post9+e462414">38712557</a> | DOI:<a href=https://doi.org/10.1161/CIRCRESAHA.123.323679>10.1161/CIRCRESAHA.123.323679</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38712557</guid>
<pubDate>Tue, 07 May 2024 06:00:00 -0400</pubDate>
<dc:creator>Stefanos Zafeiropoulos</dc:creator>
<dc:creator>Umair Ahmed</dc:creator>
<dc:creator>Alexandra Bekiaridou</dc:creator>
<dc:creator>Naveen Jayaprakash</dc:creator>
<dc:creator>Ibrahim T Mughrabi</dc:creator>
<dc:creator>Nafiseh Saleknezhad</dc:creator>
<dc:creator>Chrystal Chadwick</dc:creator>
<dc:creator>Anna Daytz</dc:creator>
<dc:creator>Izumi Kurata-Sato</dc:creator>
<dc:creator>Yemil Atish-Fregoso</dc:creator>
<dc:creator>Kaitlin Carroll</dc:creator>
<dc:creator>Yousef Al-Abed</dc:creator>
<dc:creator>Marat Fudim</dc:creator>
<dc:creator>Christopher Puleo</dc:creator>
<dc:creator>George Giannakoulas</dc:creator>
<dc:creator>Mark Nicolls</dc:creator>
<dc:creator>Betty Diamond</dc:creator>
<dc:creator>Stavros Zanos</dc:creator>
<dc:date>2024-05-07</dc:date>
<dc:source>Circulation research</dc:source>
<dc:title>Ultrasound Neuromodulation of an Anti-Inflammatory Pathway at the Spleen Improves Experimental Pulmonary Hypertension</dc:title>
<dc:identifier>pmid:38712557</dc:identifier>
<dc:identifier>doi:10.1161/CIRCRESAHA.123.323679</dc:identifier>
</item>
<item>
<title>Illusion of revascularization: does anyone achieve optimal revascularization during percutaneous coronary intervention?</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38710772/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240508000928&amp;v=2.18.0.post9+e462414
      <description>This Perspective article is a form of 'pastiche', inspired by the 1993 review by Lincoff and Topol entitled 'Illusion of reperfusion', and explores how their concept continues to apply to percutaneous revascularization in patients with coronary artery disease and ischaemia. Just as Lincoff and Topol argued that reperfusion of acute myocardial infarction was facing unresolved obstacles that hampered clinical success in 1993, we propose that challenging issues are similarly jeopardizing the...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Nat Rev Cardiol. 2024 May 7. doi: 10.1038/s41569-024-01014-0. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">This Perspective article is a form of 'pastiche', inspired by the 1993 review by Lincoff and Topol entitled 'Illusion of reperfusion', and explores how their concept continues to apply to percutaneous revascularization in patients with coronary artery disease and ischaemia. Just as Lincoff and Topol argued that reperfusion of acute myocardial infarction was facing unresolved obstacles that hampered clinical success in 1993, we propose that challenging issues are similarly jeopardizing the potential benefits of stent-based angioplasty today. By analysing the appropriateness and efficacy of percutaneous coronary intervention (PCI), we emphasize the limitations of relying solely on visual angiographic guidance, which frequently leads to inappropriate stenting and overtreatment in up to one-third of patients and the associated increased risk of periprocedural myocardial infarction. The lack of optimal revascularization observed in half of patients undergoing PCI confers risks such as suboptimal physiology after PCI, residual angina and long-term stent-related events, leaving an estimated 76% of patients with an 'illusion of revascularization'. These outcomes highlight the need to refine our diagnostic tools by integrating physiological assessments with targeted intracoronary imaging and emerging strategies, such as co-registration systems and angiography-based computational methods enhanced by artificial intelligence, to achieve optimal revascularization outcomes.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38710772/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240508000928&v=2.18.0.post9+e462414">38710772</a> | DOI:<a href=https://doi.org/10.1038/s41569-024-01014-0>10.1038/s41569-024-01014-0</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38710772</guid>
<pubDate>Mon, 06 May 2024 06:00:00 -0400</pubDate>
<dc:creator>Simone Fezzi</dc:creator>
<dc:creator>Daixin Ding</dc:creator>
<dc:creator>Felix Mahfoud</dc:creator>
<dc:creator>Jiayue Huang</dc:creator>
<dc:creator>Alexandra J Lansky</dc:creator>
<dc:creator>Shengxian Tu</dc:creator>
<dc:creator>William Wijns</dc:creator>
<dc:date>2024-05-06</dc:date>
<dc:source>Nature reviews. Cardiology</dc:source>
<dc:title>Illusion of revascularization: does anyone achieve optimal revascularization during percutaneous coronary intervention?</dc:title>
<dc:identifier>pmid:38710772</dc:identifier>
<dc:identifier>doi:10.1038/s41569-024-01014-0</dc:identifier>
</item>
<item>
<title>Correction to: 2024 Heart Disease and Stroke Statistics: A Report of US and Global Data From the American Heart Association</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38709844/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240508000928&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2024 May 7;149(19):e1164. doi: 10.1161/CIR.0000000000001247. Epub 2024 May 6.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38709844/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240508000928&v=2.18.0.post9+e462414">38709844</a> | DOI:<a href=https://doi.org/10.1161/CIR.0000000000001247>10.1161/CIR.0000000000001247</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38709844</guid>
<pubDate>Mon, 06 May 2024 06:00:00 -0400</pubDate>
<dc:date>2024-05-06</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Correction to: 2024 Heart Disease and Stroke Statistics: A Report of US and Global Data From the American Heart Association</dc:title>
<dc:identifier>pmid:38709844</dc:identifier>
<dc:identifier>doi:10.1161/CIR.0000000000001247</dc:identifier>
</item>
<item>
<title>Unlocking Pathways That Improve Cardiac Function in Chronic Heart Failure: Are Ketones the Key?</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38709843/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240508000928&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2024 May 7;149(19):1490-1492. doi: 10.1161/CIRCULATIONAHA.124.069256. Epub 2024 May 6.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38709843/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240508000928&v=2.18.0.post9+e462414">38709843</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.124.069256>10.1161/CIRCULATIONAHA.124.069256</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38709843</guid>
<pubDate>Mon, 06 May 2024 06:00:00 -0400</pubDate>
<dc:creator>Satyam Sarma</dc:creator>
<dc:creator>Jason R B Dyck</dc:creator>
<dc:date>2024-05-06</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Unlocking Pathways That Improve Cardiac Function in Chronic Heart Failure: Are Ketones the Key?</dc:title>
<dc:identifier>pmid:38709843</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.124.069256</dc:identifier>
</item>
<item>
<title>Identifying Cardiomyocyte Ploidy With Nuclear Area and Volume</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38709842/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240508000928&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2024 May 7;149(19):1540-1542. doi: 10.1161/CIRCULATIONAHA.123.065507. Epub 2024 May 6.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38709842/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240508000928&v=2.18.0.post9+e462414">38709842</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.123.065507>10.1161/CIRCULATIONAHA.123.065507</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38709842</guid>
<pubDate>Mon, 06 May 2024 06:00:00 -0400</pubDate>
<dc:creator>Zehao Yao</dc:creator>
<dc:creator>Lina Bai</dc:creator>
<dc:creator>Kefei Dou</dc:creator>
<dc:creator>Yu Nie</dc:creator>
<dc:date>2024-05-06</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Identifying Cardiomyocyte Ploidy With Nuclear Area and Volume</dc:title>
<dc:identifier>pmid:38709842</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.123.065507</dc:identifier>
</item>
<item>
<title>Will HIV Break the Heart of Africans?</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38709841/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240508000928&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2024 May 7;149(19):1471-1473. doi: 10.1161/CIRCULATIONAHA.123.065836. Epub 2024 May 6.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38709841/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240508000928&v=2.18.0.post9+e462414">38709841</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.123.065836>10.1161/CIRCULATIONAHA.123.065836</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38709841</guid>
<pubDate>Mon, 06 May 2024 06:00:00 -0400</pubDate>
<dc:creator>Roger J Bedimo</dc:creator>
<dc:creator>Fiona Strasserking</dc:creator>
<dc:creator>Pablo Tebas</dc:creator>
<dc:date>2024-05-06</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Will HIV Break the Heart of Africans?</dc:title>
<dc:identifier>pmid:38709841</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.123.065836</dc:identifier>
</item>
<item>
<title>Stroke Science and Care Since the Founding of the American Heart Association</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38709839/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240508000928&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2024 May 7;149(19):1469-1470. doi: 10.1161/CIRCULATIONAHA.123.065471. Epub 2024 May 6.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38709839/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240508000928&v=2.18.0.post9+e462414">38709839</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.123.065471>10.1161/CIRCULATIONAHA.123.065471</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38709839</guid>
<pubDate>Mon, 06 May 2024 06:00:00 -0400</pubDate>
<dc:creator>Mitchell S V Elkind</dc:creator>
<dc:date>2024-05-06</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Stroke Science and Care Since the Founding of the American Heart Association</dc:title>
<dc:identifier>pmid:38709839</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.123.065471</dc:identifier>
</item>
<item>
<title>Low-Dose Rivaroxaban Plus Aspirin in Patients With Peripheral Artery Disease Undergoing Lower Extremity Revascularization With and Without Concomitant Coronary Artery Disease: Insights From VOYAGER PAD</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38709838/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240508000928&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2024 May 7;149(19):1536-1539. doi: 10.1161/CIRCULATIONAHA.124.068080. Epub 2024 May 6.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38709838/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240508000928&v=2.18.0.post9+e462414">38709838</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.124.068080>10.1161/CIRCULATIONAHA.124.068080</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38709838</guid>
<pubDate>Mon, 06 May 2024 06:00:00 -0400</pubDate>
<dc:creator>Justin T Morrison</dc:creator>
<dc:creator>Mario Enrico Canonico</dc:creator>
<dc:creator>Sonia S Anand</dc:creator>
<dc:creator>Manesh R Patel</dc:creator>
<dc:creator>Eike Sebastian Debus</dc:creator>
<dc:creator>Mark R Nehler</dc:creator>
<dc:creator>Connie N Hess</dc:creator>
<dc:creator>Judith Hsia</dc:creator>
<dc:creator>Warren H Capell</dc:creator>
<dc:creator>Eva Muehlhofer</dc:creator>
<dc:creator>Lloyd P Haskell</dc:creator>
<dc:creator>Scott D Berkowitz</dc:creator>
<dc:creator>Rupert M Bauersachs</dc:creator>
<dc:creator>Marc P Bonaca</dc:creator>
<dc:date>2024-05-06</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Low-Dose Rivaroxaban Plus Aspirin in Patients With Peripheral Artery Disease Undergoing Lower Extremity Revascularization With and Without Concomitant Coronary Artery Disease: Insights From VOYAGER PAD</dc:title>
<dc:identifier>pmid:38709838</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.124.068080</dc:identifier>
</item>
<item>
<title>Adducin Regulates Sarcomere Disassembly During Cardiomyocyte Mitosis</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38708635/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240508000928&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS: These results highlight an important mechanism for coordinating cytoskeletal morphological changes during cardiomyocyte mitosis.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2024 May 6. doi: 10.1161/CIRCULATIONAHA.122.059102. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: Recent interest in understanding cardiomyocyte cell cycle has been driven by potential therapeutic applications in cardiomyopathy. However, despite recent advances, cardiomyocyte mitosis remains a poorly understood process. For example, it is unclear how sarcomeres are disassembled during mitosis to allow the abscission of daughter cardiomyocytes.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: Here, we use a proteomics screen to identify adducin, an actin capping protein previously not studied in cardiomyocytes, as a regulator of sarcomere disassembly. We generated many adeno-associated viruses and cardiomyocyte-specific genetic gain-of-function models to examine the role of adducin in neonatal and adult cardiomyocytes in vitro and in vivo.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: We identify adducin as a regulator of sarcomere disassembly during mammalian cardiomyocyte mitosis. α/γ-adducins are selectively expressed in neonatal mitotic cardiomyocytes, and their levels decline precipitously thereafter. Cardiomyocyte-specific overexpression of various splice isoforms and phospho-isoforms of α-adducin in identified Thr445/Thr480 phosphorylation of a short isoform of α-adducin as a potent inducer of neonatal cardiomyocyte sarcomere disassembly. Concomitant overexpression of this α-adducin variant along with γ-adducin resulted in stabilization of the adducin complex and persistent sarcomere disassembly in adult mice, which is mediated by interaction with α-actinin.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: These results highlight an important mechanism for coordinating cytoskeletal morphological changes during cardiomyocyte mitosis.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38708635/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240508000928&v=2.18.0.post9+e462414">38708635</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.122.059102>10.1161/CIRCULATIONAHA.122.059102</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38708635</guid>
<pubDate>Mon, 06 May 2024 06:00:00 -0400</pubDate>
<dc:creator>Feng Xiao</dc:creator>
<dc:creator>Ngoc Uyen Nhi Nguyen</dc:creator>
<dc:creator>Ping Wang</dc:creator>
<dc:creator>Shujuan Li</dc:creator>
<dc:creator>Ching-Cheng Hsu</dc:creator>
<dc:creator>Suwannee Thet</dc:creator>
<dc:creator>Wataru Kimura</dc:creator>
<dc:creator>Xiang Luo</dc:creator>
<dc:creator>Nicholas T Lam</dc:creator>
<dc:creator>Ivan Menendez-Montes</dc:creator>
<dc:creator>Waleed Elhelaly</dc:creator>
<dc:creator>Alisson Campos Cardoso</dc:creator>
<dc:creator>Ana Helena Macedo Pereira</dc:creator>
<dc:creator>Rohit Singh</dc:creator>
<dc:creator>Sakthivel Sadayappan</dc:creator>
<dc:creator>Mohammed Kanchwala</dc:creator>
<dc:creator>Chao Xing</dc:creator>
<dc:creator>Feria A Ladha</dc:creator>
<dc:creator>J Travis Hinson</dc:creator>
<dc:creator>Roger J Hajjar</dc:creator>
<dc:creator>Joseph A Hill</dc:creator>
<dc:creator>Hesham A Sadek</dc:creator>
<dc:date>2024-05-06</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Adducin Regulates Sarcomere Disassembly During Cardiomyocyte Mitosis</dc:title>
<dc:identifier>pmid:38708635</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.122.059102</dc:identifier>
</item>
<item>
<title>Inhibition of Hmbox1 Promotes Cardiomyocyte Survival and Glucose Metabolism Through Gck Activation in Ischemia/Reperfusion Injury</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38708602/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240508000928&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS: Our studies unravel a new role for the transcriptional repressor Hmbox1 in exercise-induced physiological cardiac growth. They also highlight the therapeutic potential of targeting Hmbox1 to improve myocardial survival and glucose metabolism after I/R injury.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2024 May 6. doi: 10.1161/CIRCULATIONAHA.123.067592. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: Exercise-induced physiological cardiac growth regulators may protect the heart from ischemia/reperfusion (I/R) injury. Homeobox-containing 1 (Hmbox1), a homeobox family member, has been identified as a putative transcriptional repressor and is downregulated in the exercised heart. However, its roles in exercise-induced physiological cardiac growth and its potential protective effects against cardiac I/R injury remain largely unexplored.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: We studied the function of Hmbox1 in exercise-induced physiological cardiac growth in mice after 4 weeks of swimming exercise. Hmbox1 expression was then evaluated in human heart samples from deceased patients with myocardial infarction and in the animal cardiac I/R injury model. Its role in cardiac I/R injury was examined in mice with adeno-associated virus 9 (AAV9) vector-mediated Hmbox1 knockdown and in those with cardiac myocyte-specific Hmbox1 ablation. We performed RNA sequencing, promoter prediction, and binding assays and identified glucokinase (Gck) as a downstream effector of Hmbox1. The effects of Hmbox1 together with Gck were examined in cardiomyocytes to evaluate their cell size, proliferation, apoptosis, mitochondrial respiration, and glycolysis. The function of upstream regulator of Hmbox1, ETS1, was investigated through ETS1 overexpression in cardiac I/R mice in vivo.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: We demonstrated that Hmbox1 downregulation was required for exercise-induced physiological cardiac growth. Inhibition of Hmbox1 increased cardiomyocyte size in isolated neonatal rat cardiomyocytes and human embryonic stem cell-derived cardiomyocytes but did not affect cardiomyocyte proliferation. Under pathological conditions, Hmbox1 was upregulated in both human and animal postinfarct cardiac tissues. Furthermore, both cardiac myocyte-specific Hmbox1 knockout and AAV9-mediated Hmbox1 knockdown protected against cardiac I/R injury and heart failure. Therapeutic effects were observed when sh-Hmbox1 AAV9 was administered after I/R injury. Inhibition of Hmbox1 activated the Akt/mTOR/P70S6K pathway and transcriptionally upregulated Gck, leading to reduced apoptosis and improved mitochondrial respiration and glycolysis in cardiomyocytes. ETS1 functioned as an upstream negative regulator of Hmbox1 transcription, and its overexpression was protective against cardiac I/R injury.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: Our studies unravel a new role for the transcriptional repressor Hmbox1 in exercise-induced physiological cardiac growth. They also highlight the therapeutic potential of targeting Hmbox1 to improve myocardial survival and glucose metabolism after I/R injury.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38708602/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240508000928&v=2.18.0.post9+e462414">38708602</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.123.067592>10.1161/CIRCULATIONAHA.123.067592</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38708602</guid>
<pubDate>Mon, 06 May 2024 06:00:00 -0400</pubDate>
<dc:creator>Yihua Bei</dc:creator>
<dc:creator>Yujiao Zhu</dc:creator>
<dc:creator>Jingwen Zhou</dc:creator>
<dc:creator>Songwei Ai</dc:creator>
<dc:creator>Jianhua Yao</dc:creator>
<dc:creator>Mingming Yin</dc:creator>
<dc:creator>Meiyu Hu</dc:creator>
<dc:creator>Weitong Qi</dc:creator>
<dc:creator>Michail Spanos</dc:creator>
<dc:creator>Lin Li</dc:creator>
<dc:creator>Meng Wei</dc:creator>
<dc:creator>Zhenzhen Huang</dc:creator>
<dc:creator>Juan Gao</dc:creator>
<dc:creator>Chang Liu</dc:creator>
<dc:creator>Petra H van der Kraak</dc:creator>
<dc:creator>Guoping Li</dc:creator>
<dc:creator>Zhiyong Lei</dc:creator>
<dc:creator>Joost P G Sluijter</dc:creator>
<dc:creator>Junjie Xiao</dc:creator>
<dc:date>2024-05-06</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Inhibition of Hmbox1 Promotes Cardiomyocyte Survival and Glucose Metabolism Through Gck Activation in Ischemia/Reperfusion Injury</dc:title>
<dc:identifier>pmid:38708602</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.123.067592</dc:identifier>
</item>
<item>
<title>Six-vessel fenestrated physician-modiﬁed stent grafts for treating thoracic aortic dissecting aneurysm and giant abdominal aortic aneurysm</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38703144/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240508000928&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2024 May 4:ehae214. doi: 10.1093/eurheartj/ehae214. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38703144/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240508000928&v=2.18.0.post9+e462414">38703144</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae214>10.1093/eurheartj/ehae214</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38703144</guid>
<pubDate>Sat, 04 May 2024 06:00:00 -0400</pubDate>
<dc:creator>Wei Liu</dc:creator>
<dc:creator>Chi Cui</dc:creator>
<dc:creator>Bisi Wang</dc:creator>
<dc:date>2024-05-04</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Six-vessel fenestrated physician-modiﬁed stent grafts for treating thoracic aortic dissecting aneurysm and giant abdominal aortic aneurysm</dc:title>
<dc:identifier>pmid:38703144</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae214</dc:identifier>
</item>
<item>
<title>Discontinuation of renin-angiotensin system inhibitors brings no benefits in severe chronic kidney disease</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38703142/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240508000928&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2024 May 4:ehae248. doi: 10.1093/eurheartj/ehae248. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38703142/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240508000928&v=2.18.0.post9+e462414">38703142</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae248>10.1093/eurheartj/ehae248</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38703142</guid>
<pubDate>Sat, 04 May 2024 06:00:00 -0400</pubDate>
<dc:creator>Massimo Volpe</dc:creator>
<dc:creator>Carlo Patrono</dc:creator>
<dc:date>2024-05-04</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Discontinuation of renin-angiotensin system inhibitors brings no benefits in severe chronic kidney disease</dc:title>
<dc:identifier>pmid:38703142</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae248</dc:identifier>
</item>
<item>
<title>Weekly journal scan: intravascular imaging to guide percutaneous coronary intervention-ready for prime time?</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38703139/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240508000928&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2024 May 4:ehae242. doi: 10.1093/eurheartj/ehae242. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38703139/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240508000928&v=2.18.0.post9+e462414">38703139</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae242>10.1093/eurheartj/ehae242</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38703139</guid>
<pubDate>Sat, 04 May 2024 06:00:00 -0400</pubDate>
<dc:creator>Rocco Vergallo</dc:creator>
<dc:creator>Carlo Patrono</dc:creator>
<dc:date>2024-05-04</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Weekly journal scan: intravascular imaging to guide percutaneous coronary intervention-ready for prime time?</dc:title>
<dc:identifier>pmid:38703139</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae242</dc:identifier>
</item>
<item>
<title>Isolated right-sided pericardial effusion following hybrid ablation for long-standing atrial fibrillation</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38703137/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240508000928&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2024 May 4:ehae210. doi: 10.1093/eurheartj/ehae210. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38703137/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240508000928&v=2.18.0.post9+e462414">38703137</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae210>10.1093/eurheartj/ehae210</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38703137</guid>
<pubDate>Sat, 04 May 2024 06:00:00 -0400</pubDate>
<dc:creator>Yahang Tan</dc:creator>
<dc:creator>Yirao Tao</dc:creator>
<dc:creator>Zhe Wang</dc:creator>
<dc:date>2024-05-04</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Isolated right-sided pericardial effusion following hybrid ablation for long-standing atrial fibrillation</dc:title>
<dc:identifier>pmid:38703137</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae210</dc:identifier>
</item>
<item>
<title>No benefit of apoA-I infusion after myocardial infarction</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38702389/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240508000928&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Nat Rev Cardiol. 2024 May 3. doi: 10.1038/s41569-024-01031-z. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38702389/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240508000928&v=2.18.0.post9+e462414">38702389</a> | DOI:<a href=https://doi.org/10.1038/s41569-024-01031-z>10.1038/s41569-024-01031-z</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38702389</guid>
<pubDate>Fri, 03 May 2024 06:00:00 -0400</pubDate>
<dc:creator>Gregory B Lim</dc:creator>
<dc:date>2024-05-03</dc:date>
<dc:source>Nature reviews. Cardiology</dc:source>
<dc:title>No benefit of apoA-I infusion after myocardial infarction</dc:title>
<dc:identifier>pmid:38702389</dc:identifier>
<dc:identifier>doi:10.1038/s41569-024-01031-z</dc:identifier>
</item>
<item>
<title>FLT3L governs the development of partially overlapping hematopoietic lineages in humans and mice</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38701783/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240508000928&amp;v=2.18.0.post9+e462414
      <description>FMS-related tyrosine kinase 3 ligand (FLT3L), encoded by FLT3LG, is a hematopoietic factor essential for the development of natural killer (NK) cells, B cells, and dendritic cells (DCs) in mice. We describe three humans homozygous for a loss-of-function FLT3LG variant with a history of various recurrent infections, including severe cutaneous warts. The patients' bone marrow (BM) was hypoplastic, with low levels of hematopoietic progenitors, particularly myeloid and B cell precursors. Counts of B...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Cell</b>. 2024 May 2:S0092-8674(24)00404-5. doi: 10.1016/j.cell.2024.04.009. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">FMS-related tyrosine kinase 3 ligand (FLT3L), encoded by FLT3LG, is a hematopoietic factor essential for the development of natural killer (NK) cells, B cells, and dendritic cells (DCs) in mice. We describe three humans homozygous for a loss-of-function FLT3LG variant with a history of various recurrent infections, including severe cutaneous warts. The patients' bone marrow (BM) was hypoplastic, with low levels of hematopoietic progenitors, particularly myeloid and B cell precursors. Counts of B cells, monocytes, and DCs were low in the patients' blood, whereas the other blood subsets, including NK cells, were affected only moderately, if at all. The patients had normal counts of Langerhans cells (LCs) and dermal macrophages in the skin but lacked dermal DCs. Thus, FLT3L is required for B cell and DC development in mice and humans. However, unlike its murine counterpart, human FLT3L is required for the development of monocytes but not NK cells.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38701783/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240508000928&v=2.18.0.post9+e462414">38701783</a> | DOI:<a href=https://doi.org/10.1016/j.cell.2024.04.009>10.1016/j.cell.2024.04.009</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38701783</guid>
<pubDate>Fri, 03 May 2024 06:00:00 -0400</pubDate>
<dc:creator>Mana Momenilandi</dc:creator>
<dc:creator>Romain Lévy</dc:creator>
<dc:creator>Steicy Sobrino</dc:creator>
<dc:creator>Jingwei Li</dc:creator>
<dc:creator>Chantal Lagresle-Peyrou</dc:creator>
<dc:creator>Hossein Esmaeilzadeh</dc:creator>
<dc:creator>Antoine Fayand</dc:creator>
<dc:creator>Corentin Le Floc'h</dc:creator>
<dc:creator>Antoine Guérin</dc:creator>
<dc:creator>Erika Della Mina</dc:creator>
<dc:creator>Debra Shearer</dc:creator>
<dc:creator>Ottavia M Delmonte</dc:creator>
<dc:creator>Ahmad Yatim</dc:creator>
<dc:creator>Kevin Mulder</dc:creator>
<dc:creator>Mathieu Mancini</dc:creator>
<dc:creator>Darawan Rinchai</dc:creator>
<dc:creator>Adeline Denis</dc:creator>
<dc:creator>Anna-Lena Neehus</dc:creator>
<dc:creator>Karla Balogh</dc:creator>
<dc:creator>Sarah Brendle</dc:creator>
<dc:creator>Hassan Rokni-Zadeh</dc:creator>
<dc:creator>Majid Changi-Ashtiani</dc:creator>
<dc:creator>Yoann Seeleuthner</dc:creator>
<dc:creator>Caroline Deswarte</dc:creator>
<dc:creator>Boris Bessot</dc:creator>
<dc:creator>Cassandre Cremades</dc:creator>
<dc:creator>Marie Materna</dc:creator>
<dc:creator>Axel Cederholm</dc:creator>
<dc:creator>Masato Ogishi</dc:creator>
<dc:creator>Quentin Philippot</dc:creator>
<dc:creator>Omer Beganovic</dc:creator>
<dc:creator>Mania Ackermann</dc:creator>
<dc:creator>Margareta Wuyts</dc:creator>
<dc:creator>Taushif Khan</dc:creator>
<dc:creator>Sébastien Fouéré</dc:creator>
<dc:creator>Florian Herms</dc:creator>
<dc:creator>Johan Chanal</dc:creator>
<dc:creator>Boaz Palterer</dc:creator>
<dc:creator>Julie Bruneau</dc:creator>
<dc:creator>Thierry J Molina</dc:creator>
<dc:creator>Stéphanie Leclerc-Mercier</dc:creator>
<dc:creator>Jean-Luc Prétet</dc:creator>
<dc:creator>Leila Youssefian</dc:creator>
<dc:creator>Hassan Vahidnezhad</dc:creator>
<dc:creator>Nima Parvaneh</dc:creator>
<dc:creator>Kristl G Claeys</dc:creator>
<dc:creator>Rik Schrijvers</dc:creator>
<dc:creator>Marine Luka</dc:creator>
<dc:creator>Philippe Pérot</dc:creator>
<dc:creator>Jacques Fourgeaud</dc:creator>
<dc:creator>Céline Nourrisson</dc:creator>
<dc:creator>Philippe Poirier</dc:creator>
<dc:creator>Emmanuelle Jouanguy</dc:creator>
<dc:creator>Stéphanie Boisson-Dupuis</dc:creator>
<dc:creator>Jacinta Bustamante</dc:creator>
<dc:creator>Luigi D Notarangelo</dc:creator>
<dc:creator>Neil Christensen</dc:creator>
<dc:creator>Nils Landegren</dc:creator>
<dc:creator>Laurent Abel</dc:creator>
<dc:creator>Nico Marr</dc:creator>
<dc:creator>Emmanuelle Six</dc:creator>
<dc:creator>David Langlais</dc:creator>
<dc:creator>Tim Waterboer</dc:creator>
<dc:creator>Florent Ginhoux</dc:creator>
<dc:creator>Cindy S Ma</dc:creator>
<dc:creator>Stuart G Tangye</dc:creator>
<dc:creator>Isabelle Meyts</dc:creator>
<dc:creator>Nico Lachmann</dc:creator>
<dc:creator>Jiafen Hu</dc:creator>
<dc:creator>Mohammad Shahrooei</dc:creator>
<dc:creator>Xavier Bossuyt</dc:creator>
<dc:creator>Jean-Laurent Casanova</dc:creator>
<dc:creator>Vivien Béziat</dc:creator>
<dc:date>2024-05-03</dc:date>
<dc:source>Cell</dc:source>
<dc:title>FLT3L governs the development of partially overlapping hematopoietic lineages in humans and mice</dc:title>
<dc:identifier>pmid:38701783</dc:identifier>
<dc:identifier>doi:10.1016/j.cell.2024.04.009</dc:identifier>
</item>
<item>
<title>Small-molecule-induced epigenetic rejuvenation promotes SREBP condensation and overcomes barriers to CNS myelin regeneration</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38701782/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240508000928&amp;v=2.18.0.post9+e462414
      <description>Remyelination failure in diseases like multiple sclerosis (MS) was thought to involve suppressed maturation of oligodendrocyte precursors; however, oligodendrocytes are present in MS lesions yet lack myelin production. We found that oligodendrocytes in the lesions are epigenetically silenced. Developing a transgenic reporter labeling differentiated oligodendrocytes for phenotypic screening, we identified a small-molecule epigenetic-silencing-inhibitor (ESI1) that enhances myelin production and...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Cell</b>. 2024 Apr 25:S0092-8674(24)00400-8. doi: 10.1016/j.cell.2024.04.005. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">Remyelination failure in diseases like multiple sclerosis (MS) was thought to involve suppressed maturation of oligodendrocyte precursors; however, oligodendrocytes are present in MS lesions yet lack myelin production. We found that oligodendrocytes in the lesions are epigenetically silenced. Developing a transgenic reporter labeling differentiated oligodendrocytes for phenotypic screening, we identified a small-molecule epigenetic-silencing-inhibitor (ESI1) that enhances myelin production and ensheathment. ESI1 promotes remyelination in animal models of demyelination and enables de novo myelinogenesis on regenerated CNS axons. ESI1 treatment lengthened myelin sheaths in human iPSC-derived organoids and augmented (re)myelination in aged mice while reversing age-related cognitive decline. Multi-omics revealed that ESI1 induces an active chromatin landscape that activates myelinogenic pathways and reprograms metabolism. Notably, ESI1 triggered nuclear condensate formation of master lipid-metabolic regulators SREBP1/2, concentrating transcriptional co-activators to drive lipid/cholesterol biosynthesis. Our study highlights the potential of targeting epigenetic silencing to enable CNS myelin regeneration in demyelinating diseases and aging.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38701782/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240508000928&v=2.18.0.post9+e462414">38701782</a> | DOI:<a href=https://doi.org/10.1016/j.cell.2024.04.005>10.1016/j.cell.2024.04.005</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38701782</guid>
<pubDate>Fri, 03 May 2024 06:00:00 -0400</pubDate>
<dc:creator>Xuezhao Liu</dc:creator>
<dc:creator>Dazhuan Eric Xin</dc:creator>
<dc:creator>Xiaowen Zhong</dc:creator>
<dc:creator>Chuntao Zhao</dc:creator>
<dc:creator>Zhidan Li</dc:creator>
<dc:creator>Liguo Zhang</dc:creator>
<dc:creator>Adam J Dourson</dc:creator>
<dc:creator>Lindsay Lee</dc:creator>
<dc:creator>Shreya Mishra</dc:creator>
<dc:creator>Arman E Bayat</dc:creator>
<dc:creator>Eva Nicholson</dc:creator>
<dc:creator>William L Seibel</dc:creator>
<dc:creator>Bingfang Yan</dc:creator>
<dc:creator>Joel Mason</dc:creator>
<dc:creator>Bradley J Turner</dc:creator>
<dc:creator>David G Gonsalvez</dc:creator>
<dc:creator>William Ong</dc:creator>
<dc:creator>Sing Yian Chew</dc:creator>
<dc:creator>Balaram Ghosh</dc:creator>
<dc:creator>Sung Ok Yoon</dc:creator>
<dc:creator>Mei Xin</dc:creator>
<dc:creator>Zhigang He</dc:creator>
<dc:creator>Jason Tchieu</dc:creator>
<dc:creator>Michael Wegner</dc:creator>
<dc:creator>Klaus-Armin Nave</dc:creator>
<dc:creator>Robin J M Franklin</dc:creator>
<dc:creator>Ranjan Dutta</dc:creator>
<dc:creator>Bruce D Trapp</dc:creator>
<dc:creator>Ming Hu</dc:creator>
<dc:creator>Matthew A Smith</dc:creator>
<dc:creator>Michael P Jankowski</dc:creator>
<dc:creator>Samantha K Barton</dc:creator>
<dc:creator>Xuelian He</dc:creator>
<dc:creator>Q Richard Lu</dc:creator>
<dc:date>2024-05-03</dc:date>
<dc:source>Cell</dc:source>
<dc:title>Small-molecule-induced epigenetic rejuvenation promotes SREBP condensation and overcomes barriers to CNS myelin regeneration</dc:title>
<dc:identifier>pmid:38701782</dc:identifier>
<dc:identifier>doi:10.1016/j.cell.2024.04.005</dc:identifier>
</item>
<item>
<title>A very rare complication: Amplatzer Septal Occluder dislodgement 6 days later under Ecpella</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38701047/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240508000928&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2024 May 3:ehae238. doi: 10.1093/eurheartj/ehae238. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38701047/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240508000928&v=2.18.0.post9+e462414">38701047</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae238>10.1093/eurheartj/ehae238</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38701047</guid>
<pubDate>Fri, 03 May 2024 06:00:00 -0400</pubDate>
<dc:creator>Yu-Chuan Chuang</dc:creator>
<dc:creator>Tsun-Jui Liu</dc:creator>
<dc:creator>Wei-Wen Lin</dc:creator>
<dc:date>2024-05-03</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>A very rare complication: Amplatzer Septal Occluder dislodgement 6 days later under Ecpella</dc:title>
<dc:identifier>pmid:38701047</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae238</dc:identifier>
</item>
<item>
<title>Paradoxical progress of function and fibrosis in FLNC cardiomyopathy after therapy</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38701022/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240508000928&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2024 May 3:ehae241. doi: 10.1093/eurheartj/ehae241. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38701022/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240508000928&v=2.18.0.post9+e462414">38701022</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae241>10.1093/eurheartj/ehae241</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38701022</guid>
<pubDate>Fri, 03 May 2024 06:00:00 -0400</pubDate>
<dc:creator>Yangjie Li</dc:creator>
<dc:creator>Yuanwei Xu</dc:creator>
<dc:creator>Yucheng Chen</dc:creator>
<dc:date>2024-05-03</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Paradoxical progress of function and fibrosis in FLNC cardiomyopathy after therapy</dc:title>
<dc:identifier>pmid:38701022</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae241</dc:identifier>
</item>





























</channel>
</rss>